R Sterpu1, H Ichou2, I Mahé1, E Mortier3. 1. Service de médecine interne, hôpital Louis-Mourier (AP-HP), 178, rue des Renouillers, 92700 Colombes, France. 2. Service de microbiologie, hôpital Louis-Mourier (AP-HP), 178, rue des Renouillers, 92700 Colombes, France. 3. Service de médecine interne, hôpital Louis-Mourier (AP-HP), 178, rue des Renouillers, 92700 Colombes, France. Electronic address: emmanuel.mortier@lmr.aphp.fr.
Abstract
INTRODUCTION: Infection by human parvovirus B19 (erythrovirus B19) is common and usually asymptomatic during childhood conferring lasting protection against a new infection. Parvovirus B19 infection may cause erythema infectiosum (5th disease) and aplastic crisis. Secondary symptomatic parvovirus B19 infection in the same patient is rare and its physiopathology is not always clear. CASE REPORT: A 48-year-old HIV-infected female patient presented within 5 years two acute episodes of parvovirus B19 infection although her CD4 cells count was above 500/mm(3). Absence of specific antibodies production after the first episode and persisting parvovirus viremia suggested viral reactivation rather than re-infection. During the second episode, specific antibodies were produced. CONCLUSION: Similarly to most DNA viruses, parvovirus B19 reactivation is possible in HIV-infected patients while effectively treated by antiretroviral therapy.
INTRODUCTION:Infection by human parvovirus B19 (erythrovirus B19) is common and usually asymptomatic during childhood conferring lasting protection against a new infection. Parvovirus B19 infection may cause erythema infectiosum (5th disease) and aplastic crisis. Secondary symptomatic parvovirus B19 infection in the same patient is rare and its physiopathology is not always clear. CASE REPORT: A 48-year-old HIV-infected female patient presented within 5 years two acute episodes of parvovirus B19 infection although her CD4 cells count was above 500/mm(3). Absence of specific antibodies production after the first episode and persisting parvovirus viremia suggested viral reactivation rather than re-infection. During the second episode, specific antibodies were produced. CONCLUSION: Similarly to most DNA viruses, parvovirus B19 reactivation is possible in HIV-infectedpatients while effectively treated by antiretroviral therapy.
Authors: Joaquín Escobar-Sevilla; Antonio Bustos Merlo; Carmen Garcia Martínez; Juan Diego Mediavilla Garcia Journal: Eur J Case Rep Intern Med Date: 2020-06-25
Authors: Man Xu; Katarzyna Leskinen; Tommaso Gritti; Valerija Groma; Johanna Arola; Anna Lepistö; Taina Sipponen; Päivi Saavalainen; Maria Söderlund-Venermo Journal: Front Microbiol Date: 2022-05-24 Impact factor: 6.064